MedCity News January 27, 2026
We have to cover medical nutrition therapy for those who need it most, including Medicare beneficiaries. Almost all commercial payers are already doing this – the government needs to catch up.
Recently, the Trump administration announced expanded Medicare coverage of GLP-1s for beneficiaries with a body mass index (BMI) of 35 or greater, or a BMI of 27 or greater with certain chronic conditions including prediabetes, heart disease and failure, and kidney disease.
This is a massive and needed expansion of coverage. Research has shown that this class of drugs is remarkably effective in reducing obesity and related chronic conditions such as heart disease, kidney disease, and diabetes.
But GLP-1s on their own are not a silver bullet.
Individuals...
Today's Sponsors
Today's Sponsor